论文部分内容阅读
目的探讨不同亚型干扰素联合利巴韦林治疗慢性丙型肝炎(CHC)的疗效。方法随机选取CHC患者79例,分为治疗组41例、对照组38例。治疗组给予重组人干扰素α-2b(IFNα-2b),对照组给予重组人干扰素α-1b(IFNα-1b),2组均联合利巴韦林,总疗程为48周。分别于治疗前及治疗后第12、24、48、72周采集静脉血,化验肝功能、血常规及HCV-RNA,检测治疗前、治疗后72周肝脏LSM值。比较2组相关参数差异。结果治疗组及对照组基于RVR、EVR、ETVR、SVR比较,差异有统计学意义;治疗组及对照组不同治疗时间肝功能复常率χ~2及P值分别为:12周:χ~2=0.0006,P=0.981、24周:χ~2=5.144,P=0.023、48周:χ~2=3.918,P=0.048及72周:χ~2=6.244,P=0.012,差异具有统计学意义;治疗组及对照组肝脏LSM值在48周及72周t值分别为-2.035(P=0.045),-3.081(P=0.003),差异具有统计学意义。结论 IFNα-2b联合利巴韦林组较IFNα-1b联合利巴韦林组治疗CHC具有优越性。
Objective To investigate the efficacy of different subtypes of interferon in combination with ribavirin in the treatment of chronic hepatitis C (CHC). Methods A total of 79 CHC patients were randomly divided into treatment group (41 cases) and control group (38 cases). The treatment group received recombinant human interferon α-2b (IFNα-2b), while the control group received recombinant human interferon α-1b (IFNα-1b). Both groups were combined with ribavirin for a total of 48 weeks. Venous blood was collected before treatment and 12th, 24th, 48th and 72th week after treatment. Liver function, blood routine and HCV-RNA were detected. LSM values of liver before and 72 weeks after treatment were measured. Compare the difference between the two groups of related parameters. Results The treatment group and the control group had statistically significant differences based on RVR, EVR, ETVR and SVR. Χ ~ 2 and P values of the treatment group and the control group at different treatment time were: 12 weeks: χ ~ 2 = 0.0006, P = 0.981, 24 weeks: χ ~ 2 = 5.144, P = 0.023,48 weeks: χ ~ 2 = 3.918, P = 0.048 and 72 weeks: χ ~ 2 = 6.244, P = 0.012, the difference was statistically significant Significance of liver LSM values in treatment group and control group were -2.035 (P = 0.045) and 3.081 (P = 0.003) at 48 weeks and 72 weeks, respectively. The difference was statistically significant. Conclusion IFNα-2b combined with ribavirin is superior to IFNα-1b and ribavirin in the treatment of CHC.